TSBX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 32.10%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Turnstone Biologics Insider Trading History Chart

Turnstone Biologics Share Price & Price History

^$2.55

▲ +0.04 (1.59%)

As of 07/26/2024 01:00 AM ET

Days: 30 | 90 | 365

I’m giving you the name of this investment for free

From Porter & Company | Ad

This key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documentary I will provide you with all the details of this one-of-a-kind investment.

Let me explain in this new documentary video

Turnstone Biologics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/25/2023	Versant Ventures V, Llc	Major Shareholder	Buy	225,000	$12.00	$2,700,000.00	2,726,322
7/20/2023	Rishi Gupta	Director	Buy	416,666	$12.00	$4,999,992.00	3,099,265

I’m giving you the name of this investment for free

From Porter & Company | Ad

This key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documentary I will provide you with all the details of this one-of-a-kind investment.

Let me explain in this new documentary video

SEC Filings (Institutional Ownership Changes) for Turnstone Biologics (NASDAQ:TSBX)

52.51% of Turnstone Biologics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Turnstone Biologics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/17/2024	Zimmer Partners LP	179,026	$0.47M	0.0%	+271.4%	0.774%
4/17/2024	Kathleen S. Wright Associates Inc.	42,553	$0.11M	0.1%	N/A	0.184%
2/15/2024	PFM Health Sciences LP	633,313	$1.61M	0.1%	-58.5%	2.742%
2/15/2024	Caas Capital Management LP	45,831	$0.12M	0.0%	-40.1%	0.198%
12/6/2023	Citigroup Inc.	7,524	$30K	0.0%	N/A	0.033%
11/15/2023	Sectoral Asset Management Inc.	517,648	$2.04M	0.4%	N/A	2.266%
11/14/2023	Eventide Asset Management LLC	708,317	$2.79M	0.1%	N/A	3.101%
11/13/2023	FMR LLC	2,830,284	$11.15M	0.0%	N/A	12.392%
11/7/2023	New York State Common Retirement Fund	18,867	$74K	0.0%	N/A	0.083%

Data available starting January 2016

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

Today's Range

Now: $2.55

$2.48

$2.59

50 Day Range

MA: $2.62

$2.24

$2.99

52 Week Range

Now: $2.55

$1.63

$13.20

Volume

22,022 shs

Average Volume

157,472 shs

Market Capitalization

$58.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Turnstone Biologics?: Turnstone Biologics' top insider investors include:
Rishi Gupta (Director)
Versant Ventures V, Llc (Major Shareholder)
Learn More about top insider investors at Turnstone Biologics.